Skip to main content

Advertisement

SpringerLink
Log in

Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Standard treatment of cutaneous lupus erythematosus (CLE) includes preventive measures such as smoking cessation and photoprotection associated with topical therapies and antimalarial agents, which are recommended as first-line systemic treatment. In more severe disease, alternative therapeutic options include immunosuppressive and immunomodulatory drugs. Recently, the development of specific tools to assess CLE activity and the publication of European CLE guidelines have improved the management of CLE. Moreover, several biologic agents are currently being studied specifically in CLE or in systemic lupus erythematosus with assessment of skin involvement and may be promising therapies. However, improvement of the management of CLE remains a major unmet need. In this review, we summarize current concepts in the management of CLE as well as future approaches for more targeted treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Med (Baltim). 1993;72:113–24.

    Article  CAS  Google Scholar 

  2. Lipsker D. The need to revisit the nosology of cutaneous lupus erythematosus: the current terminology and morphologic classification of cutaneous LE: difficult, incomplete and not always applicable. Lupus. 2010;19:1047–9.

    Article  CAS  PubMed  Google Scholar 

  3. Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;48–49:14–9.

    Article  CAS  PubMed  Google Scholar 

  4. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4:471–5.

    Article  CAS  PubMed  Google Scholar 

  5. Schmitt V, Meuth AM, Amler S, Kuehn E, Haust M, Messer G, et al. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol. 2010;162:64–73.

    Article  CAS  PubMed  Google Scholar 

  6. Durosaro O, Davis MDP, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965–2005: a population-based study. Arch Dermatol. 2009;145:249–53.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Deligny C, Clyti E, Sainte-Marie D, Couppie P, Huong DLT, Piette JC, et al. Incidence of chronic cutaneous lupus erythematosus in French Guiana: a retrospective population-based study. Arthritis Care Res. 2010;62:279–82.

    Article  Google Scholar 

  8. Grönhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011;164:1335–41.

    Article  PubMed  Google Scholar 

  9. Arnaud L, Fagot J-P, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev. 2014;13:1082–9.

    Article  PubMed  Google Scholar 

  10. Biazar C, Sigges J, Patsinakidis N, Ruland V, Amler S, Bonsmann G, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2013;12:444–54.

    Article  PubMed  Google Scholar 

  11. Kunz M, König IR, Schillert A, Kruppa J, Ziegler A, Grallert H, et al. Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. Exp Dermatol. 2015;24:510–5.

    Article  CAS  PubMed  Google Scholar 

  12. Szczęch J, Samotij D, Werth VP, Reich A. Trigger factors of cutaneous lupus erythematosus: a review of current literature. Lupus. 2017;26:791–807.

    Article  CAS  PubMed  Google Scholar 

  13. Yu C, Chang C, Zhang J. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review. J Autoimmun. 2013;41:34–45.

    Article  CAS  PubMed  Google Scholar 

  14. Felten R, Dervovic E, Chasset F, Gottenberg J-E, Sibilia J, Scher F, et al. The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. Autoimmun Rev. 2018;17:781–90.

    Article  PubMed  Google Scholar 

  15. Kuhn A, Aberer E, Bata-Csörgő Z, Caproni M, Dreher A, Frances C, et al. S2k guideline for treatment of cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol JEADV. 2016;31:389–404.

    Article  CAS  PubMed  Google Scholar 

  16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Chasset F, Francès C, Barete S, Amoura Z, Arnaud L. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015;72:634–9.

    Article  CAS  PubMed  Google Scholar 

  18. Chasset F, Bouaziz J-D, Costedoat-Chalumeau N, Francès C, Arnaud L. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol. 2017;177:188–96.

    Article  CAS  PubMed  Google Scholar 

  19. Chasset F, Tounsi T, Cesbron E, Barbaud A, Francès C, Arnaud L. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;78:342–50.

    Article  CAS  PubMed  Google Scholar 

  20. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550–8.

    Article  CAS  PubMed  Google Scholar 

  21. Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res. 2011;63(Suppl 11):S37–46.

    Article  Google Scholar 

  22. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125:889–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bein D, Kuehn E, Meuth AM, Amler S, Haust M, Nyberg F, et al. Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI. J Eur Acad Dermatol Venereol JEADV. 2011;25:652–9.

    Article  CAS  PubMed  Google Scholar 

  24. Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol Hoboken NJ. 2017;69:376–86.

    Article  CAS  Google Scholar 

  25. van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet Lond Engl. 2018;392:1330–9.

    Article  Google Scholar 

  26. Jiang F, Li S, Jia C. Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative meta-analysis. Clin Rheumatol. 2015;34:1885–92.

    Article  PubMed  Google Scholar 

  27. Turchin I, Bernatsky S, Clarke AE, St-Pierre Y, Pineau CA. Cigarette smoking and cutaneous damage in systemic lupus erythematosus. J Rheumatol. 2009;36:2691–3.

    Article  PubMed  Google Scholar 

  28. Bourré-Tessier J, Peschken CA, Bernatsky S, Joseph L, Clarke AE, Fortin PR, et al. Association of smoking with cutaneous manifestations in systemic lupus erythematosus. Arthritis Care Res. 2013;65:1275–80.

    Article  Google Scholar 

  29. Piette EW, Foering KP, Chang AY, Okawa J, Ten Have TR, Feng R, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol. 2012;148:317–22.

    Article  PubMed  Google Scholar 

  30. Parodis I, Sjöwall C, Jönsen A, Ramsköld D, Zickert A, Frodlund M, et al. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev. 2017;16:343–51.

    Article  CAS  PubMed  Google Scholar 

  31. Ruland V, Haust M, Stilling RM, Metze D, Amler S, Ruzicka T, et al. Updated analysis of standardized photoprovocation in patients with cutaneous lupus erythematosus. Arthritis Care Res. 2013;65:767–76.

    Article  CAS  Google Scholar 

  32. Wozniacka A, Lesiak A, Boncela J, Smolarczyk K, McCauliffe DP, Sysa-Jedrzejowska A. The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br J Dermatol. 2008;159:1124–30.

    CAS  PubMed  Google Scholar 

  33. Sontheimer C, Liggitt D, Elkon KB. Ultraviolet B irradiation causes stimulator of interferon genes-dependent production of protective type i interferon in mouse skin by recruited inflammatory monocytes. Arthritis Rheumatol Hoboken NJ. 2017;69:826–36.

    Article  CAS  Google Scholar 

  34. Kuhn A, Herrmann M, Kleber S, Beckmann-Welle M, Fehsel K, Martin-Villalba A, et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum. 2006;54:939–50.

    Article  PubMed  Google Scholar 

  35. Scholtissek B, Zahn S, Maier J, Klaeschen S, Braegelmann C, Hoelzel M, et al. Immunostimulatory endogenous nucleic acids drive the lesional inflammation in cutaneous lupus erythematosus. J Invest Dermatol. 2017;137:1484–92.

    Article  CAS  PubMed  Google Scholar 

  36. Yin Q, Xu X, Lin Y, Lv J, Zhao L, He R. Ultraviolet B irradiation induces skin accumulation of plasmacytoid dendritic cells: a possible role for chemerin. Autoimmunity. 2014;47:185–92.

    Article  CAS  PubMed  Google Scholar 

  37. Chasset F, Arnaud L. Targeting interferons and their pathways in systemic lupus erythematosus. Autoimmun Rev. 2017;17:44–52.

    Article  CAS  PubMed  Google Scholar 

  38. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159:237–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Sarkar MK, Hile GA, Tsoi LC, Xing X, Liu J, Liang Y, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018;77:1653–64.

    Article  CAS  PubMed  Google Scholar 

  40. Kuhn A, Gensch K, Haust M, Meuth A-M, Boyer F, Dupuy P, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. 2011;64:37–48.

    Article  CAS  PubMed  Google Scholar 

  41. Zahn S, Graef M, Patsinakidis N, Landmann A, Surber C, Wenzel J, et al. Ultraviolet light protection by a sunscreen prevents interferon-driven skin inflammation in cutaneous lupus erythematosus. Exp Dermatol. 2014;23:516–8.

    Article  CAS  PubMed  Google Scholar 

  42. Heine G, Lahl A, Müller C, Worm M. Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year. Br J Dermatol. 2010;163:863–5.

    Article  CAS  PubMed  Google Scholar 

  43. Scott JF, Das LM, Ahsanuddin S, Qiu Y, Binko AM, Traylor ZP, et al. Oral vitamin D rapidly attenuates inflammation from sunburn: an interventional study. J Invest Dermatol. 2017;137:2078–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Cutillas-Marco E, Marquina-Vila A, Grant WB, Vilata-Corell JJ, Morales-Suárez-Varela MM. Vitamin D and cutaneous lupus erythematosus: effect of vitamin D replacement on disease severity. Lupus. 2014;23:615–23.

    Article  CAS  PubMed  Google Scholar 

  45. Marzano AV, Lazzari R, Polloni I, Crosti C, Fabbri P, Cugno M. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol. 2011;165:335–41.

    Article  CAS  PubMed  Google Scholar 

  46. Guicciardi F, Atzori L, Marzano AV, Tavecchio S, Girolomoni G, Colato C, et al. Are there distinct clinical and pathological features distinguishing Idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study. J Am Acad Dermatol. 2019.

  47. Grönhagen CM, Fored CM, Linder M, Granath F, Nyberg F. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012;167:296–305.

    Article  CAS  PubMed  Google Scholar 

  48. Roenigk HH, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis. 1980;25:281–5.

    PubMed  Google Scholar 

  49. Spann CR, Callen JP, Klein JB, Kulick KB. Clinical, serologic and immunogenetic studies in patients with chronic cutaneous (discoid) lupus erythematosus who have verrucous and/or hypertrophic skin lesions. J Rheumatol. 1988;15:256–61.

    CAS  PubMed  Google Scholar 

  50. Ting WW, Sontheimer RD. Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations. Lupus. 2001;10:171–84.

    Article  CAS  PubMed  Google Scholar 

  51. Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol. 2009;34:776–80.

    Article  CAS  PubMed  Google Scholar 

  52. Pothinamthong P, Janjumratsang P. A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. J Med Assoc Thail Chotmaihet Thangphaet. 2012;95:933–40.

    Google Scholar 

  53. Kuhn A, Gensch K, Haust M, Schneider SW, Bonsmann G, Gaebelein-Wissing N, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2011;65:54–64, 64.e1–2.

  54. Milam EC, Ramachandran S, Franks AG. Treatment of scarring alopecia in discoid variant of chronic cutaneous lupus erythematosus with tacrolimus lotion, 0.3. JAMA Dermatol. 2015;151:1113–6.

    Article  PubMed  Google Scholar 

  55. Jemec GBE, Ullman S, Goodfield M, Bygum A, Olesen AB, Berth-Jones J, et al. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. Br J Dermatol. 2009;161:1365–70.

    Article  CAS  PubMed  Google Scholar 

  56. Seiger E, Roland S, Goldman S. Cutaneous lupus treated with topical tretinoin: a case report. Cutis. 1991;47:351–5.

    CAS  PubMed  Google Scholar 

  57. Terao M, Matsui S, Katayama I. Two cases of refractory discoid lupus erythematosus successfully treated with topical tocoretinate. Dermatol Online J. 2011;17:15.

    PubMed  Google Scholar 

  58. Newman AJ, Schneider A, Blumetti B, Barr J. Chronic cutaneous lupus erythematosus and topical clindamycin. BMJ Case Rep. 2018. https://doi.org/10.1136/bcr-2018-226728.

    Article  PubMed  Google Scholar 

  59. Kraak JH, Van Ketel W, Prakken JR, Van Zwet W. The value of hydroxychloroquine (plaquenil) for the treatment of chronic discoid lupus erythematosus; a double blind triaL. Dermatologica. 1965;130:293–305.

    Article  CAS  PubMed  Google Scholar 

  60. Yokogawa N, Tanikawa A, Amagai M, Kato Y, Momose Y, Arai S, et al. Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). Mod Rheumatol Jpn Rheum Assoc. 2013;23:318–22.

    Article  CAS  Google Scholar 

  61. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20–8.

    Article  CAS  PubMed  Google Scholar 

  62. Mittal L, Zhang L, Feng R, Werth VP. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study. J Am Acad Dermatol. 2018;78(100–106):e1.

    Google Scholar 

  63. Costedoat-Chalumeau N, Amoura Z, Hulot J-S, Aymard G, Leroux G, Marra D, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66:821–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Francès C, Cosnes A, Duhaut P, Zahr N, Soutou B, Ingen-Housz-Oro S, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol. 2012;148:479–84.

    Article  PubMed  Google Scholar 

  65. Chasset F, Arnaud L, Costedoat-Chalumeau N, Zahr N, Bessis D, Francès C. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. J Am Acad Dermatol. 2016;74(693–699):e3.

    Google Scholar 

  66. Chasset F, Arnaud L, Jachiet M, Monfort J-B, Bouaziz J-D, Cordoliani F, et al. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: a multicenter observational study. J Am Acad Dermatol. 2018;78(107–114):e1.

    Google Scholar 

  67. Zeidi M, Kim HJ, Werth VP. Increased myeloid dendritic cells and TNF-α expression predicts poor response to hydroxychloroquine in cutaneous lupus erythematosus. J Invest Dermatol. 2019;139:324–32.

    Article  CAS  PubMed  Google Scholar 

  68. Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF, American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415–22.

    Article  PubMed  Google Scholar 

  69. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453–60.

    Article  PubMed  Google Scholar 

  70. Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;2016(123):1386–94.

    Article  Google Scholar 

  71. Albert DA, Hadler NM, Ropes MW. Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus? Arthritis Rheum. 1979;22:945–53.

    Article  CAS  PubMed  Google Scholar 

  72. Sigges J, Biazar C, Landmann A, Ruland V, Patsinakidis N, Amler S, et al. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev. 2013;12:694–702.

    Article  PubMed  Google Scholar 

  73. Al Sawah S, Zhang X, Zhu B, Magder LS, Foster SA, Iikuni N, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus Sci Med. 2015;2:e000066.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Rúa-Figueroa I, López-Longo F, Del Campo V, Galindo-Izquierdo M, Uriarte E, Torre-Cisneros J, Vela P, Tomero E, Narváez J, Olivé A, Freire M, Salgado E, Andreu JL, Martínez-Taboada V, Calvo-Alén J, Hernández-Cruz B, Raya E, Quevedo V, Expósito Pérez L, Fernández-Nebro A, Ibañez M, Pascual ÈV, Rúa-Figueroa D, Naranjo A, Pego-Reigosa JM. Bacteremia in systemic lupus erythematosus patients from RELESSER: risk factors, clinical and microbiological characteristics and outcomes. J Rheumatol. 2019. https://doi.org/10.3899/jrheum.180882.

    Article  PubMed  Google Scholar 

  75. Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016;12:731–42.

    Article  CAS  PubMed  Google Scholar 

  76. Nakazawa F, Matsuno H, Yudoh K, Katayama R, Sawai T, Uzuki M, et al. Methotrexate inhibits rheumatoid synovitis by inducing apoptosis. J Rheumatol. 2001;28:1800–8.

    CAS  PubMed  Google Scholar 

  77. Barrera P, Boerbooms AM, Janssen EM, Sauerwein RW, Gallati H, Mulder J, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 1993;36:1070–9.

    Article  CAS  PubMed  Google Scholar 

  78. Islam MN, Hossain M, Haq SA, Alam MN, Ten Klooster PM, Rasker JJ. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis. 2012;15:62–8.

    Article  CAS  PubMed  Google Scholar 

  79. Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int. 1998;18:59–62.

    Article  CAS  PubMed  Google Scholar 

  80. Wenzel J, Brähler S, Bauer R, Bieber T, Tüting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005;153:157–62.

    Article  CAS  PubMed  Google Scholar 

  81. Mazaud C, Fardet L. Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials. Br J Dermatol. 2017;177:978–86.

    Article  CAS  PubMed  Google Scholar 

  82. Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992;127:513–8.

    Article  CAS  PubMed  Google Scholar 

  83. Kuhn A, Patsinakidis N, Luger T. Alitretinoin for cutaneous lupus erythematosus. J Am Acad Dermatol. 2012;67:e123–6.

    Article  PubMed  Google Scholar 

  84. Huang Y-C, Cheng Y-C. Isotretinoin treatment for acne and risk of depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;76(1068–1076):e9.

    Google Scholar 

  85. Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306:103–24.

    Article  CAS  PubMed  Google Scholar 

  86. Klebes M, Wutte N, Aberer E. Dapsone as second-line treatment for cutaneous lupus erythematosus? A retrospective analysis of 34 patients and a review of the literature. Dermatol Basel Switz. 2016;232:91–6.

    Article  CAS  Google Scholar 

  87. Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica. 1986;172:214–7.

    Article  CAS  PubMed  Google Scholar 

  88. de Risi-Pugliese T, Cohen Aubart F, Haroche J, Moguelet P, Grootenboer-Mignot S, Mathian A, et al. Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 new cases and a literature review of 118 cases. Semin Arthritis Rheum. 2018;48:83–9.

    Article  PubMed  Google Scholar 

  89. Begon E, Chosidow O, Wolkenstein P. [Disulone]. Ann Dermatol Venereol. 2004;131:1062–73.

    Article  CAS  PubMed  Google Scholar 

  90. Cummins DL, Gaspari AA. Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: discordant effects on minimal erythema dose and sunburn cell formation. Br J Dermatol. 2004;151:458–64.

    Article  CAS  PubMed  Google Scholar 

  91. Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol. 1983;108:461–6.

    Article  CAS  PubMed  Google Scholar 

  92. Cuadrado MJ, Karim Y, Sanna G, Smith E, Khamashta MA, Hughes GRV. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. 2005;118:246–50.

    Article  CAS  PubMed  Google Scholar 

  93. Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, Vilardell-Tarres M, Ordi-Ros J. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol. 2012;166:616–23.

    Article  CAS  PubMed  Google Scholar 

  94. Briani C, Zara G, Rondinone R, Iaccarino L, Ruggero S, Toffanin E, et al. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity. 2005;38:549–55.

    Article  CAS  PubMed  Google Scholar 

  95. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O’Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology. 2002;59:1872–5.

    Article  CAS  PubMed  Google Scholar 

  96. Bastuji-Garin S, Ochonisky S, Bouche P, Gherardi RK, Duguet C, Djerradine Z, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002;119:1020–6.

    Article  CAS  PubMed  Google Scholar 

  97. Cesbron E, Bessis D, Jachiet M, Lipsker D, Cordel N, Bouaziz JD, Bagot M, Arnaud L, Barbaud A, Francès C, Chasset F, Study Group of Systemic Diseases in Dermatology (Étude des Maladies Systémiques en Dermatologie). Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study. J Am Acad Dermatol. 2018;79(1):162–5.

    Article  PubMed  Google Scholar 

  98. https://www.ansm.sante.fr/Activites/Recommandations-Temporaires-d-Utilisation-RTU/Liste-des-specialites-faisant-actuellement-l-objet-d-une-RTU/Liste-des-specialites-faisant-l-objet-d-une-RTU/THALIDOMIDE-CELGENE-50-mg-gelule. Accessed 1 Mar 2019.

  99. Uhl K, Cox E, Rogan R, Zeldis JB, Hixon D, Furlong L-A, et al. Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. programme. Drug Saf. 2006;29:321–9.

    Article  CAS  PubMed  Google Scholar 

  100. Chasset F, Arnaud L, Francès C. Thromboprophylaxis and thalidomide in the noncancer setting: toward an algorithm that is based on patient risk factors and underlying disease? J Am Acad Dermatol. 2018;79:e47–8.

    Article  PubMed  Google Scholar 

  101. Arnaud L, Mathian A, Ruffatti A, Erkan D, Tektonidou M, Cervera R, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;13:281–91.

    Article  CAS  PubMed  Google Scholar 

  102. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Braunstein I, Goodman NG, Rosenbach M, Okawa J, Shah A, Krathen M, et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol. 2012;66:571–82.

    Article  CAS  PubMed  Google Scholar 

  104. Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther. 2012;14:R265.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Fennira F, Chasset F, Soubrier M, Cordel N, Petit A, Francès C. Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients. J Am Acad Dermatol. 2016;74:1248–51.

    Article  PubMed  Google Scholar 

  106. Cunninghame Graham DS, Morris DL, Bhangale TR, Criswell LA, Syvänen A-C, Rönnblom L, et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 2011;7:e1002341.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Lessard CJ, Adrianto I, Ice JA, Wiley GB, Kelly JA, Glenn SB, et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet. 2012;90:648–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Schafer PH, Ye Y, Wu L, Kosek J, Ringheim G, Yang Z, et al. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. Ann Rheum Dis. 2018;77:1516–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219–28.

    Article  CAS  PubMed  Google Scholar 

  110. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol JASN. 2009;20:1103–12.

    Article  CAS  PubMed  Google Scholar 

  111. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886–95.

    Article  CAS  PubMed  Google Scholar 

  112. Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;65(717–721):e2.

    Google Scholar 

  113. Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007;156:1321–7.

    Article  CAS  PubMed  Google Scholar 

  114. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol. 1991;127:515–22.

    Article  CAS  PubMed  Google Scholar 

  115. Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76:476–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Piette JC, Frances C, Roy S, Papo T, Godeau P. High-dose immunoglobulins in the treatment of refractory cutaneous lupus erythematosus: open trial in 5 patients. Arthritis Rheum. 1995;38(suppl 9):S304.

    Google Scholar 

  117. Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatol Treat. 2004;15:46–50.

    Article  CAS  Google Scholar 

  118. Ky C, Swasdibutra B, Khademi S, Desai S, Laquer V, Grando SA. Efficacy of intravenous immunoglobulin monotherapy in patients with cutaneous lupus erythematosus: results of proof-of-concept study. Dermatol Rep. 2015;7:5804.

    Article  CAS  Google Scholar 

  119. Truchuelo MT, Boixeda P, Alcántara J, Moreno C, de las Heras E, Olasolo PJ. Pulsed dye laser as an excellent choice of treatment for lupus tumidus: a prospective study. J Eur Acad Dermatol Venereol JEADV. 2012;26:1272–9.

  120. Erceg A, Bovenschen HJ, van de Kerkhof PCM, de Jong EMJG, Seyger MMB. Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. J Am Acad Dermatol. 2009;60:626–32.

    Article  PubMed  Google Scholar 

  121. Rerknimitr P, Tekacharin N, Panchaprateep R, Wititsuwannakul J, Tangtanatakul P, Hirankarn N, et al. Pulsed-dye laser as an adjuvant treatment for discoid lupus erythematosus: a randomized, controlled trial. J Dermatol Treat. 2018;1–6.

  122. Atzmony L, Amitay-Laish I, Gurion R, Shahal-Zimra Y, Hodak E. Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: a single-centre experience. J Eur Acad Dermatol Venereol JEADV. 2015;29:2382–9.

    Article  CAS  PubMed  Google Scholar 

  123. Malik MI, Litzow M, Hogan W, Patnaik M, Murad MH, Prokop LJ, et al. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res. 2014;49:100–6.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Boeckler P, Liu V, Lipsker D. Extracorporeal photopheresis in recalcitrant lupus erythematosus. Clin Exp Dermatol. 2009;34:e295–6.

    Article  CAS  PubMed  Google Scholar 

  125. Morruzzi C, Liu V, Bohbot A, Cribier B, Lipsker D. Four cases of photopheresis treatment for cutaneous lupus erythematosus refractory to standard therapy. Ann Dermatol Venereol. 2009;136:861–7.

    Article  CAS  PubMed  Google Scholar 

  126. Felten R, Dervovic E, Chasset F, Gottenberg JE, Sibilia J, Scher F, Arnaud L. The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. Autoimmun Rev. 2018;17(8):781–90.

    Article  PubMed  Google Scholar 

  127. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215–26.

    Article  CAS  PubMed  Google Scholar 

  128. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Kleinmann J-F, Tubach F, Le Guern V, Mathian A, Richez C, Saadoun D, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev. 2017;16:650–7.

    Article  CAS  PubMed  Google Scholar 

  130. Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol Hoboken NJ. 2015;67:1586–91.

    Article  CAS  Google Scholar 

  131. Quelhas da Costa R, Aguirre-Alastuey ME, Isenberg DA, Saracino AM. Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018;154:1432–40.

  132. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–31.

    Article  CAS  PubMed  Google Scholar 

  133. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Wenzel J, Landmann A, Vorwerk G, Kuhn A. High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus. Exp Dermatol. 2018;27:95–7.

    Article  CAS  PubMed  Google Scholar 

  135. Iaccarino L, Andreoli L, Bocci EB, Bortoluzzi A, Ceccarelli F, Conti F, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018;86:1–8.

    Article  CAS  PubMed  Google Scholar 

  136. Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, Drappa J, Wang L, Greth W, CD1067 study investigators. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Merrill JT, Furie R, Werth VP, Khamashta M, Drappa J, Wang L, et al. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5:e000284.

    Article  PubMed  PubMed Central  Google Scholar 

  138. https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html. Accessed 1 Mar 2019.

  139. Richez C, Truchetet M-E, Kostine M, Schaeverbeke T, Bannwarth B. Efficacy of baricitinib in the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2017;18:1399–407.

    Article  CAS  PubMed  Google Scholar 

  140. Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Lond Engl. 2018;392:222–31.

    Article  CAS  Google Scholar 

  141. Zimmermann N, Wolf C, Schwenke R, Lüth A, Schmidt F, Engel K, Lee-Kirsch MA, Günther C. Assessment of clinical response to janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation. JAMA Dermatol. 2019. https://doi.org/10.1001/jamadermatol.2018.5077.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Meesilpavikkai K, Dik WA, Schrijver B, van Helden-Meeuwsen CG, Versnel MA, van Hagen PM, Bijlsma EK, Ruivenkamp CAL, Oele MJ, Dalm VASH. Efficacy of baricitinib in the treatment of chilblains associated with Aicardi-Goutières syndrome, a type I interferonopathy. Arthritis Rheumatol. 2019;71(5):829–31.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet Lond Engl. 2018;392:2367–77.

    Article  CAS  Google Scholar 

  144. van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet Lond Engl. 2018;392:2378–87.

    Article  Google Scholar 

  145. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Wenzel J, van Holt N, Maier J, Vonnahme M, Bieber T, Wolf D. JAK1/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus. J Invest Dermatol. 2016;136:1281–3.

    Article  CAS  PubMed  Google Scholar 

  147. Klaeschen AS, Wolf D, Brossart P, Bieber T, Wenzel J. JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus. Exp Dermatol. 2017;26:728–30.

    Article  CAS  PubMed  Google Scholar 

  148. Presto JK, Okon LG, Feng R, Wallace DJ, Furie R, Fiorentino D, et al. Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus. Br J Dermatol. 2018;178:1308–14.

    Article  CAS  PubMed  Google Scholar 

  149. Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, Wang W, Christmann R, Gardet A, Pellerin A, Hamann S, Auluck P, Barbey C, Gulati P, Rabah D, Franchimont N. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019;129(3):1359–71.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–60.

    Article  CAS  PubMed  Google Scholar 

  151. Griffiths CEM, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–28.

    Article  CAS  PubMed  Google Scholar 

  152. De Souza A, Ali-Shaw T, Strober BE, Franks AG. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol. 2011;147:896–8.

    Article  PubMed  Google Scholar 

  153. Winchester D, Duffin KC, Hansen C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus. 2012;21:1007–10.

    Article  CAS  PubMed  Google Scholar 

  154. Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med. 2012;18:871–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5:179ra43.

  156. He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22:991–3.

    Article  CAS  PubMed  Google Scholar 

  157. Kuhn A, Meuth AM, Bein D, Amler S, Beissert S, Böhm M, et al. Revised cutaneous lupus erythematosus disease area and severity index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010;163:83–92.

    CAS  PubMed  Google Scholar 

  158. Concha JSS, Patsatsi A, Marshak-Rothstein A, Liu M-L, Sinha AA, Lee LA, et al. Advances in cutaneous lupus erythematosus and dermatomyositis: a report from the 4th international conference on cutaneous lupus erythematosus-an ongoing need for international consensus and collaborations. J Invest Dermatol. 2019;139:270–6.

  159. Ototake Y, Yamaguchi Y, Kanaoka M, Akita A, Ikeda N, Aihara M. Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients. J Dermatol. 2019;46(4):285–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sorbonne Université, Faculté de Médecine Sorbonne Université, AP-HP, Service de Dermatologie et Allergologie, Hôpital Tenon, 4 rue de la Chine, 75020, Paris CEDEX 20, France

    François Chasset & Camille Francès

Authors
  1. François Chasset
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Camille Francès
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to François Chasset.

Ethics declarations

Conflict of interest

François Chasset and Camille Francès have no conflicts of interest to declare.

Funding

No funding was received for the preparation of this review.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chasset, F., Francès, C. Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review. Drugs 79, 1199–1215 (2019). https://doi.org/10.1007/s40265-019-01151-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-019-01151-8

Search

Navigation